Literature DB >> 7853488

Encapsidation of poliovirus replicons encoding the complete human immunodeficiency virus type 1 gag gene by using a complementation system which provides the P1 capsid protein in trans.

D C Porter1, D C Ansardi, C D Morrow.   

Abstract

Poliovirus genomes which contain small regions of the human immunodeficiency virus type 1 (HIV-1) gag, pol, and env genes substituted in frame for the P1 capsid region replicate and express HIV-1 proteins as fusion proteins with the P1 capsid precursor protein upon transfection into cells (W. S. Choi, R. Pal-Ghosh, and C. D. Morrow, J. Virol. 65:2875-2883, 1991). Since these genomes, referred to as replicons, do not express capsid proteins, a complementation system was developed to encapsidate the genomes by providing P1 capsid proteins in trans from a recombinant vaccinia virus, VV-P1. Virus stocks of encapsidated replicons were generated after serial passage of the replicon genomes into cells previously infected with VV-P1 (D. C. Porter, D. C. Ansardi, W. S. Choi, and C. D. Morrow, J. Virol. 67:3712-3719, 1993). Using this system, we have further defined the role of the P1 region in viral protein expression and RNA encapsidation. In the present study, we constructed poliovirus replicons which contain the complete 1,492-bp gag gene of HIV-1 substituted for the entire P1 region of poliovirus. To investigate whether the VP4 coding region was required for the replication and encapsidation of poliovirus RNA, a second replicon in which the complete gag gene was substituted for the VP2, VP3, and VP1 capsid sequences was constructed. Transfection of replicon RNA with and without the VP4 coding region into cells resulted in similar levels of expression of the HIV-1 Gag protein and poliovirus 3CD protein, as indicated by immunoprecipitation using specific antibodies. Northern (RNA) blot analysis of RNA from transfected cells demonstrated comparable levels of RNA replication for each replicon. Transfection of the replicon genomes into cells infected with VV-P1 resulted in the encapsidation of the genomes; serial passage in the presence of VV-P1 resulted in the generation of virus stocks of encapsidated replicons. Analysis of the levels of protein expression and encapsidated replicon RNA from virus stocks after 21 serial passages of the replicon genomes with VV-P1 indicated that the replicon which contained the VP4 coding region was present at a higher level than the replicon which contained a complete substitution of the P1 capsid sequences. These differences in encapsidation, though, were not detected after only two serial passages of the replicons with VV-P1 or upon coinfection and serial passage with type 1 Sabin poliovirus.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7853488      PMCID: PMC188748     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  33 in total

1.  A poliovirus replicon containing the chloramphenicol acetyltransferase gene can be used to study the replication and encapsidation of poliovirus RNA.

Authors:  N Percy; W S Barclay; M Sullivan; J W Almond
Journal:  J Virol       Date:  1992-08       Impact factor: 5.103

2.  Complete nucleotide sequence of the AIDS virus, HTLV-III.

Authors:  L Ratner; W Haseltine; R Patarca; K J Livak; B Starcich; S F Josephs; E R Doran; J A Rafalski; E A Whitehorn; K Baumeister
Journal:  Nature       Date:  1985 Jan 24-30       Impact factor: 49.962

3.  Primary structure of poliovirus defective-interfering particle genomes and possible generation mechanisms of the particles.

Authors:  S Kuge; I Saito; A Nomoto
Journal:  J Mol Biol       Date:  1986-12-05       Impact factor: 5.469

4.  Processing determinants required for in vitro cleavage of the poliovirus P1 precursor to capsid proteins.

Authors:  M F Ypma-Wong; B L Semler
Journal:  J Virol       Date:  1987-10       Impact factor: 5.103

5.  Isolation and characterization of defective-interfering particles of poliovirus Sabin 1 strain.

Authors:  S Kajigaya; H Arakawa; S Kuge; T Koi; N Imura; A Nomoto
Journal:  Virology       Date:  1985-04-30       Impact factor: 3.616

6.  Defective interfering particles of poliovirus. I. Isolation and physical properties.

Authors:  C N Cole; D Smoler; E Wimmer; D Baltimore
Journal:  J Virol       Date:  1971-04       Impact factor: 5.103

7.  Production of infectious poliovirus from cloned cDNA is dramatically increased by SV40 transcription and replication signals.

Authors:  B L Semler; A J Dorner; E Wimmer
Journal:  Nucleic Acids Res       Date:  1984-06-25       Impact factor: 16.971

8.  Poliovirus polypeptide precursors: expression in vitro and processing by exogenous 3C and 2A proteinases.

Authors:  M J Nicklin; H G Kräusslich; H Toyoda; J J Dunn; E Wimmer
Journal:  Proc Natl Acad Sci U S A       Date:  1987-06       Impact factor: 11.205

9.  Differential antibody responses of individuals infected with AIDS-associated retroviruses surveyed using the viral core antigen p25gag expressed in bacteria.

Authors:  K S Steimer; J P Puma; M D Power; M A Powers; C George-Nascimento; J C Stephans; J A Levy; R Sanchez-Pescador; P A Luciw; P J Barr
Journal:  Virology       Date:  1986-04-15       Impact factor: 3.616

10.  A second virus-encoded proteinase involved in proteolytic processing of poliovirus polyprotein.

Authors:  H Toyoda; M J Nicklin; M G Murray; C W Anderson; J J Dunn; F W Studier; E Wimmer
Journal:  Cell       Date:  1986-06-06       Impact factor: 41.582

View more
  24 in total

1.  Construction of an infectious cDNA clone of Aichi virus (a new member of the family Picornaviridae) and mutational analysis of a stem-loop structure at the 5' end of the genome.

Authors:  J Sasaki; Y Kusuhara; Y Maeno; N Kobayashi; T Yamashita; K Sakae; N Takeda; K Taniguchi
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

2.  Expression of a membrane-anchored glycoprotein, the influenza virus hemagglutinin, by dicistronic replicons derived from the poliovirus genome.

Authors:  Marco Vignuzzi; Sylvie Gerbaud; Sylvie van der Werf; Nicolas Escriou
Journal:  J Virol       Date:  2002-05       Impact factor: 5.103

Review 3.  Foot-and-mouth disease.

Authors:  Marvin J Grubman; Barry Baxt
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

4.  Efficient replication of recombinant Enterovirus B types, carrying different P1 genes in the coxsackievirus B5 replicative backbone.

Authors:  Nina Jonsson; Anna Sävneby; Maria Gullberg; Kim Evertsson; Karin Klingel; A Michael Lindberg
Journal:  Virus Genes       Date:  2015-02-08       Impact factor: 2.332

5.  Toward a poliovirus-based simian immunodeficiency virus vaccine: correlation between genetic stability and immunogenicity.

Authors:  S Tang; R van Rij; D Silvera; R Andino
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

6.  trans-encapsidation of a poliovirus replicon by different picornavirus capsid proteins.

Authors:  X Y Jia; M Van Eden; M G Busch; E Ehrenfeld; D F Summers
Journal:  J Virol       Date:  1998-10       Impact factor: 5.103

7.  The rhinovirus type 14 genome contains an internally located RNA structure that is required for viral replication.

Authors:  K L McKnight; S M Lemon
Journal:  RNA       Date:  1998-12       Impact factor: 4.942

8.  Encapsidation of the flavivirus kunjin replicon RNA by using a complementation system providing Kunjin virus structural proteins in trans.

Authors:  A A Khromykh; A N Varnavski; E G Westaway
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

9.  Release of virus-like particles from cells infected with poliovirus replicons which express human immunodeficiency virus type 1 Gag.

Authors:  D C Porter; L R Melsen; R W Compans; C D Morrow
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

10.  Direct interaction between two viral proteins, the nonstructural protein 2C and the capsid protein VP3, is required for enterovirus morphogenesis.

Authors:  Ying Liu; Chunling Wang; Steffen Mueller; Aniko V Paul; Eckard Wimmer; Ping Jiang
Journal:  PLoS Pathog       Date:  2010-08-26       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.